AFMD (Affimed NV) Institutional Ownership : 18.70% (As of Dec. 11, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Affimed NV Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Affimed NV's institutional ownership is 18.70%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Affimed NV's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Affimed NV's Float Percentage Of Total Shares Outstanding is 94.43%.

Affimed NV Institutional Ownership Historical Data

The historical data trend for Affimed NV's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV Institutional Ownership Chart

Affimed NV Historical Data

The historical data trend for Affimed NV can be seen below:

	2024-02-29	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30
Institutional Ownership	2.07	1.64	1.65	1.66	1.54	1.46	1.43	1.03	1.03	1.03

Affimed NV Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Affimed NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

0HL9:UK A28A:Germany

Address

Gottlieb-Daimler-Strabe 2, Mannheim, BW, DEU, 68165

Website

https://www.affimed.com

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.